ViiV Healthcare reports over 99% effectiveness for Apretude (Cabotegravir Long-Acting) in real-world studies.

Sanofi has partnered with Orano Med, a branch of the Orano Group that leads in the advancement of targeted alpha therapies for cancer treatment.

uniQure N.V. has announced that the initial participant has received a dose in the Phase I/II clinical study of AMT-162.

Three novel drugs by Gan & Lee Pharmaceuticals-GZR18, GZR4, and GZR101 injections-meet primary goals in Phase 2 trials.

Amgen reveals favorable Phase 3 results for Uplizna® (inebilizumab-cdon) in treating generalized myasthenia gravis at AANEM 2024.

In a Phase 2/3 study, nipocalimab effectively controls symptoms in teenagers with generalized myasthenia gravis.

Beacon Therapeutics Reports Favorable 24-Month Results from Phase 2 SKYLINE Study of AGTC-501 in X-Linked Retinitis Pigmentosa Patients.

Topas Therapeutics released encouraging top-line outcomes from a Phase 2a study examining their leading candidate, TPM502.

Circle Pharma Begins Phase 1 Clinical Trial with CID-078, an Oral Cyclin A/B RxL Inhibitor, Administered to Initial Patients for Advanced Solid Tumors.

Transgene updates on Phase II trial for TG4001 cancer vaccine targeting recurrent or metastatic HPV16-positive cervical and anogenital cancers.

GSK shares favorable phase III findings from ANCHOR trials on depemokimab for chronic rhinosinusitis with nasal polyps.

SystImmune, Inc. has received FDA approval for its IND application regarding BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia.